Dirk Rades, Laura Doehring, Cansu Delikanli, Elisa M Groh, Sabine Bohnet, Stefan Janssen
{"title":"评估老年肺癌患者放射性肺炎的风险。","authors":"Dirk Rades, Laura Doehring, Cansu Delikanli, Elisa M Groh, Sabine Bohnet, Stefan Janssen","doi":"10.21873/anticanres.17695","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Pneumonitis is a potential complication following radiotherapy of lung cancer, particularly in elderly patients. We developed a risk score for this age group.</p><p><strong>Patients and methods: </strong>Thirteen factors were investigated in 124 elderly lung cancer patients. Factors significantly associated with symptomatic radiation pneumonitis (RP) or showing a trend were used for the score, which was compared to an existing tool created in patients of any age.</p><p><strong>Results: </strong>RP was significantly associated with mean lung dose (MLD). Trends were found for autoimmune disease and cardiovascular disease. Based on these three factors, four risk groups were designed (6-7, 8-9, 11-12, and 14 points). RP rates were 0.0% (0/25), 19.1% (9/47), 51.1% (24/47), and 80.0% (4/5). Positive (PPV) and negative (NPV) predictive values were 80.0% and 100.0%. When using the existing tool based on MLD and autoimmune disease, PPV and NPV were the same.</p><p><strong>Conclusion: </strong>The new score was highly accurate but not superior to the existing tool. The existing tool appears preferable, since it requires only two variables.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3347-3353"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Estimating the Risk of Radiation Pneumonitis in Elderly Patients With Lung Cancer.\",\"authors\":\"Dirk Rades, Laura Doehring, Cansu Delikanli, Elisa M Groh, Sabine Bohnet, Stefan Janssen\",\"doi\":\"10.21873/anticanres.17695\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>Pneumonitis is a potential complication following radiotherapy of lung cancer, particularly in elderly patients. We developed a risk score for this age group.</p><p><strong>Patients and methods: </strong>Thirteen factors were investigated in 124 elderly lung cancer patients. Factors significantly associated with symptomatic radiation pneumonitis (RP) or showing a trend were used for the score, which was compared to an existing tool created in patients of any age.</p><p><strong>Results: </strong>RP was significantly associated with mean lung dose (MLD). Trends were found for autoimmune disease and cardiovascular disease. Based on these three factors, four risk groups were designed (6-7, 8-9, 11-12, and 14 points). RP rates were 0.0% (0/25), 19.1% (9/47), 51.1% (24/47), and 80.0% (4/5). Positive (PPV) and negative (NPV) predictive values were 80.0% and 100.0%. When using the existing tool based on MLD and autoimmune disease, PPV and NPV were the same.</p><p><strong>Conclusion: </strong>The new score was highly accurate but not superior to the existing tool. The existing tool appears preferable, since it requires only two variables.</p>\",\"PeriodicalId\":8072,\"journal\":{\"name\":\"Anticancer research\",\"volume\":\"45 8\",\"pages\":\"3347-3353\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anticancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/anticanres.17695\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17695","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Estimating the Risk of Radiation Pneumonitis in Elderly Patients With Lung Cancer.
Background/aim: Pneumonitis is a potential complication following radiotherapy of lung cancer, particularly in elderly patients. We developed a risk score for this age group.
Patients and methods: Thirteen factors were investigated in 124 elderly lung cancer patients. Factors significantly associated with symptomatic radiation pneumonitis (RP) or showing a trend were used for the score, which was compared to an existing tool created in patients of any age.
Results: RP was significantly associated with mean lung dose (MLD). Trends were found for autoimmune disease and cardiovascular disease. Based on these three factors, four risk groups were designed (6-7, 8-9, 11-12, and 14 points). RP rates were 0.0% (0/25), 19.1% (9/47), 51.1% (24/47), and 80.0% (4/5). Positive (PPV) and negative (NPV) predictive values were 80.0% and 100.0%. When using the existing tool based on MLD and autoimmune disease, PPV and NPV were the same.
Conclusion: The new score was highly accurate but not superior to the existing tool. The existing tool appears preferable, since it requires only two variables.
期刊介绍：
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
